Support us on Patreon: https://www.patreon.com/speedpharmacology Follow us on Facebook: https://www.facebook.com/SpeedPharmacology/ Get Speed Pharmacology Merch Here: https://teespring.com/stores/speed-pharmacology **************************************************************************************************** Topics covered include: basic pathophysiology of hypertension, regulation of blood pressure, cardiac output, systemic vascular resistance, baroreceptors, alpha & beta receptors, vasoconstriction, vasodilation, renin-angiotensin-aldosterone system, bradykinin, nitric oxide. Mechanism of action of antihypertensive drugs and their side effects; adrenergic antagonists; alpha & beta blockers, centrally acting adrenergic agents, dihydropyridine & nondihydropyridine calcium channel blockers, loop, thiazide, potassium-sparing diuretics, renin inhibitors, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor type 1 blockers (ARBs), endothelin receptor antagonist, dopamine-1 receptor agonist, peripheral vasodilators. Drugs mentioned include; Doxazosin, Prazosin, Clonidine, Methyldopa, Amlodipine, Felodipine, Nicardipine, Nifedipine, Diltiazem, Verapamil, Furosemide, Hydrochlorothiazide, Triamterene, Spironolactone, Aliskiren, Benazepril, Captopril, Enalapril, Lisinopril, Quinapril, Ramipril, Candesartan, Irbesartan, Losartan, Olmesartan, Valsartan, Bosentan, Fenoldopam, Sodium Nitroprusside, Nitroglycerin, Hydralazine, and Minoxidil.
Views: 187605 Speed Pharmacology
Valsartan drugbank. Yang wq, li yl, jiang hq valsartan cid 60846 structure, chemical names, physical the mechanism of action is as an angiotensin 2 receptor antagonist apr 15, 2010 benefit triple combination therapy with amlodipine, and due to these mechanisms action, amlodipine produces mostly their differs from that converting enzyme (ace) no significant drug interactions involving valsartan, irbesartan, valsartan's block vasoconstrictor aldosterone secreting effects ii. Googleusercontent search. Diovan (valsartan) side effects, interactions, warning, dosage mechanism of action – Entresto (sacubitril valsartan) tablets. This is acheived by selectively blocking the binding of apr 18, 2017 sacubitril valsartan, proved superiority over other conventional heart failure management treatments, but its mechanisms action remains jan 27, 2016 this article aims to review mechanism and clinical development valsartan (lcz696), a first in class angiotensin their action, however, very different from ace inhibitors, candesartanirbesartanolmesartanvalsartan diovan official prescribing information for healthcare professionals. Diovan fda prescribing information, side effects and uses. The mechanism of action valsartan studied by hplc tof ms]. Valsartan blocks the actions of angiotensin ii, which include constricting blood vessels and activating aldosterone, to reduce pressure. Angiotensin receptor blockers (arbs)byvalson (nebivolol and valsartan). At the n4 position (a proposed structural site of action for sulfonamide allergy). Wikipedia wiki valsartan&sa u&ved 0ahukewik3bzfy4fvahuccz4khu_uaxoqfggjmae&usg afqjcnflel2_vecc3dzqzh3ari5xu14h6q"valsartan wikipediavalsartan wikipedia. The drug binds to angiotensin type i receptors (at1), working as an antagonist sep 1, 2016 diovan (valsartan) blocks the vasoconstrictor and aldosterone secreting effects of ii by selectively blocking binding at 1 receptor in many tissues, such vascular smooth muscle adrenal gland review mechanism action for entresto (sacubitril valsartan) how treatment works a neprilysin inhibitor blocker clarifies medication valsartan (diovan), is used treat high blood what valsartan, does it work (mechanism action)? Yao xue bao. See full safety, pi & boxed warning. Abbreviations ace, angiotensin mechanisms of action sacubitril valsartan on cardiac remodeling the mechanism lcz696 radcliffecardiologyangiotensin receptor blockers (arbs). Includes indications, dosage diovan clinical pharmacologymechanism of action. The mechanism of action valsartan studied by hplc tof ms] role valsartan, amlodipine and hydrochlorothiazide fixed. Diovan hct (hydrochlorothiazide valsartan) dose, indications. Wikipedia wiki valsartan&sa u&ved 0ahukewik3bzfy4fvahuccz4khu_uaxoqfggjmae&usg afqjcnflel2_vecc3dzqzh3ari5xu14h6q"valsartan wikipedia. Diovan (valsartan) dosing, indications, interactions, adverse effects arbs angiotensin receptor blockers youtube. Valsartan, diovan drug facts, side effects and dosing medicinene
Views: 479 run sparky
This animation reviews the physiological effects of Angiotensin II in the cardiovascular system that contribute to the development of atherosclerosis.
Views: 17189 Mechanisms in Medicine
Read the full article online: http://www.bmj.com/content/347/bmj.f6745 The use of β blockers, diuretics, and statins has been established to reduce cardiovascular morbidity and mortality in a variety of diseases.However, although statins reduce cardiovascular events and mortality in patients with coronary artery disease or equivalent risk factors, debate continues about their role in primary prevention in lower risk populations. Despite the overwhelming benefits of these drugs on cardiovascular outcomes, recent evidence suggests that long term use may increase the risk of diabetes. Large trials examining cardiovascular outcomes and mortalities suggested an increased incidence of new onset diabetes with long term use of diuretics. Likewise, other studies have reported an increased incidence of diabetes in people treated with statins, prompting the US Food and Drug Administration to release a safety label change in 2012. Furthermore, β blockers have been implicated in impaired glucose metabolism, especially with diuretics. Large scale studies with serial glucose measurements examining the association between these drugs and new onset diabetes in patients with impaired glucose tolerance are limited. We reanalysed data from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) study to examine the relation between risk of new onset diabetes and use of β blockers, thiazide diuretics, or statins in treatment naïve patients. In this study, the researchers set out to examine the degree to which use of β blockers, statins, and diuretics in patients with impaired glucose tolerance and other cardiovascular risk factors is associated with new onset diabetes.
Views: 1273 The BMJ
Ranolazine in Patients with Chronic Angina
Views: 1184 American College of Cardiology Video Archive
At the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), held in Valencia, Spain, Paul Richardson, MD, from Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, discusses the clinical development and recent FDA approval of the novel polydisperse oligonucleotide defibrotide for the treatment of patients with severe veno-occlusive disease (sVOD) following a hematopoietic stem cell transplant (HSCT). In three retrospective studies, defibrotide was associated with a survival benefit over what would have been expected. During EBMT the overriding message regarding VOD was "treat early", because if you wait the efficacy of drug diminishes as the patient gets sicker. Prof. Paul Richardson also discusses the safety profile of defibrotide, and how effective it has been in Pediatrics, and the new treatment guidelines created by EBMT.
Sugar and the beating heart: the conundrum of heart failure in diabetes Air date: Wednesday, February 7, 2018, 3:00:00 PM Category: WALS - Wednesday Afternoon Lectures Runtime: 01:02:50 Description: NIH Director’s Wednesday Afternoon Lecture Series Dr. Abel is internationally recognized for his research on the molecular mechanisms responsible for cardiac dysfunction in obesity, type 2 diabetes, and type 1 diabetes, and for studies of the role of mitochondrial dysfunction in the development of insulin resistance, obesity, and its complications. Dr. Abel earned his medical degree with distinction from the University of the West Indies in Kingston, Jamaica. He was a Rhodes Scholar and clinical research fellow with Professor John G. Ledingham at the University of Oxford, England, where he also earned a Ph.D. in physiology. He completed an internship and residency in medicine at McGraw Medical Center, a part of Northwestern University Medical School, where he served as chief resident of internal medicine at the VA Lakeside Medical Center. He was a clinical and research fellow and instructor at Harvard Medical School before joining the faculty at the University of Utah in 2000. Dr. Abel has earned many awards including the Van Meter Prize of the American Thyroid Association in 2001 and the 2012 Gerald D. Aurbach Award, from The Endocrine Society for "outstanding" contributions to endocrine research. He was elected Chair of the Board of Scientific Counselors of the NIH National Institute of Diabetes and Digestive and Kidney Diseases, and now serves as a member of the advisory council of the National Heart, Lung, and Blood Institute. He was chair of the Sarnoff Cardiovascular Research Foundation's Scientific Committee from 2012 to 2013, and is a fellow of the American Heart Association and the American College of Physicians. He was recently elected as president of the Endocrine Society. Dr. Abel is an elected member of the American Society for Clinical Investigation, American Clinical and Climatological Association, and the Association of American Physicians. He was elected to the National Academy of Medicine in October 2015. For more information go to https://oir.nih.gov/wals/2017-2018/sugar-beating-heart-conundrum-heart-failure-diabetes Author: E. Dale Abel, M.D., Ph.D., Francois M. Abboud Chair in Internal Medicine and John B. Stokes Chair in Diabetes Research; Chair and Department Executive Officer, Department of Internal Medicine, University of Iowa, Carver College of Medicine Permanent link: https://videocast.nih.gov/launch.asp?23703
Views: 579 nihvcast
On episode 003 of the CCRx podcast, we discuss the new medications that have received FDA approval in December 2017. We also walk-through our first evidence-based patient case. The case handout can be found under episode 003 at www.corconsultrx.com/podcast along with hyperlinks to all the clinical trials that were discussed during the episode. Follow us on all social media platforms at @corconsultrx
Views: 339 CorConsult Rx: Evidence-Based Medicine
http://ace-inhibitors.info If you have been put on beta blockers as part of your treatments for diabetes, then you are certainly not alone. Millions of Americans are taking beta blockers as a means to control the rhythms of their heart. When you have diabetes, you often have hypertension or high blood pressure, and beta blockers help to control this. In fact, these same drugs are used by people who need to be calm or have steady hands, such as musicians, surgeons or even professional billiards players!
Views: 106 aceinhibitors2
http://www.ibiology.org/ibioseminars/cell-biology/robert-lefkowitz-part-2.html In part 2 of the lecture, recent discoveries about how Beta-arrestins not only desensitize the receptors but also mediate their endocytosis, as well as independent signaling pathways, are reviewed. Also covered is how these new discoveries provide a basis for designing novel classes of pharmacological agents which can promote signaling exclusively down either the G protein or Beta-arrestin mediated pathways, so called biased agonists. See more at www.ibiology.org
Views: 20150 iBiology
The N Engl J Med image of the week shows a tattoo with cutaneous manifestations indicating a skin reaction. You are offered aspergillosis, coccidiodomycosis, granuloma annulare, sarcoidosis, and syphilis. This quiz is rather trivial. The N Engl J Med topic is idiopathic pulmonary fibrosis, a relentless, interstitial inflammatory and fibrotic lung disease that ends fatally. Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. Investigators conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. Pirfenidone has well-established antifibrotic and anti-inflammatory properties in various in vitro systems and animal models of fibrosis. In a phase 3 study, investigators randomly assigned 555 patients with idiopathic pulmonary fibrosis to receive either oral pirfenidone (2403 mg per day) or placebo for 52 weeks. Both these reports showed a benefit. Acetylcysteine has been suggested as a beneficial treatment for idiopathic pulmonary fibrosis, although data from placebo-controlled studies are lacking. Now we have such data and acetylcysteine did not help. Thymic stromal lymphopoietin (TSLP) is a hemopoietic cytokine, which signals throughout a heterodimeric receptor complex composed of the thymic stromal lymphopoietin receptor and the interleukin-7 receptor alpha chain. In a double-blind, placebo-controlled study, investigators randomly assigned 31 patients with mild allergic asthma to receive three monthly doses of the anti-TSLP antibody, AMG 157 (700 mg), or placebo intravenously. They then conducted allergen challenges on days 42 and 84 to evaluate the effect of AMG 157 in reducing the maximum percentage decrease in the forced expiratory volume in 1 second (FEV1). The studies convincingly show a role for TSLP in extrinsic asthma. The use of vaccines to prevent and control cholera is currently under debate. Shanchol is one of the two oral cholera vaccines prequalified by the World Health Organization; however, its effectiveness under field conditions and the protection it confers in the first months after administration remain unknown. We look at a field study indicating that the oral vaccine works. We also review briefly how cholera toxin causes diarrhea. The critical care review is on traumatic intracranial hypertension and how the condition should be combatted. We review briefly how quick contact with neurosurgeons in emergencies might avoid traumatic intracranial hypertension altogether. The N Engl J Med case of the week is a patient with a complicated pneumonia and a delayed diagnosis. The rate of death from overdoses of prescription opioids in the United States more than quadrupled between 1999 and 2010, far exceeding the combined death toll from cocaine and heroin overdoses. I am not sure why this is the case either. Public health officials also seem to be clueless. The fixed-dose combination of any two antihypertensive drugs from different drug classes is typically more effective in reducing blood pressure than a dose increase of component monotherapy. Lancet investigators assessed the efficacy and safety of a fixed-dose combination of a vasodilating β blocker (nebivolol) and an angiotensin II receptor blocker (valsartan) in adults with hypertension. I am not sure how these banal drug studies get published in the Lancet either. We review still another epidemiological study showing the relationship between blood pressure and 12 cardiovascular diseases. The next investigators aimed to assess the change in blood pressure management between 1994 and 2011 in England with a series of annual surveys. Looks like treatment of hypertension in the UK is improving. The first Lancet review is on atrial septal defects; the second on myocardial remodeling after infarction and during heart failure. The Battle of Bosworth Field was the last significant battle of the Wars of the Roses, the civil war between the Houses of Lancaster and York that raged across England in the latter half of the 15th century. Winner was Henry Tudor; loser was Richard III, the last Plantagenet king so maligned by William Shakespeare as an evil hunchback. We now inspect his recently exhumed skeleton and check out his Cobb score to see if Shakespeare was correct, at least regarding Richard's spine. Join me for all the clinical excitement on Wednesday at 17.00 in the ECRC or per Webex.
Views: 501 Clinical Journal Club
Garlic does more than just invigorate your palate and ward off vampires; it’s also a smelly superfood health aid. The spice is a highly nutritious vegetable with very few calories, containing trace amounts of other nutrients that contribute to its universal status of a powerful, beneficial healer. The natural medicinal ingredient, both as a fresh plant and supplement, can strengthen immune function and boost overall well-being. Garlic’s delicious flavor and health benefits have led to a steady increase in demand. The average garlic consumption per capita per year is 2 pounds. A healthy adult can safely consume up to four cloves of garlic each day, according to the University of Maryland Medical Center, with each one weighing about a gram. The body-strengthening effects of this herb are thought to be due to its active ingredient allicin. This is what gives garlic its distinctive taste and smell. Whether you take your garlic powdered, salted, or minced or in supplement form, you can reap the surprising benefits of this multipurpose herb for optimal health. 1. TREATS ACNE This herb may not be found in acne products’ list of ingredients, but it can serve as a natural topical treatment to get rid of blemishes. Allicin, the organic compound in garlic, has the ability to stop the damaging effects of radicals and kill bacteria, according to a 2009 study published in the journal Angewandte Chemie. In its decomposed form — sulfenic acid — allicin produces a fast reaction with radicals, which makes it a valuable herb for treating acne scars, skin diseases, and allergies. 2. TREATS HAIR LOSS A head full of hair that smells like garlic could help in the treatment of hair loss. The herb’s extremely high sulfur content contains keratin, the protein hair is made of. This stimulates fortification and growth. A 2007 study published in the Indian Journal of Dermatology, Venerology and Leprology found the use of a garlic gel added to the therapeutic efficacy of topical betamethasone valerate for alopecia areata treatment can be effective to induce hair re-growth. 3. FIGHTS COMMON COLD Garlic’s allicin can serve as a health aid during times of illness. Rene Ficek, a registered dietician and a lead nutrition expert at Seattle Sutton's Healthy Eating in Illinois told Medical Daily in an email: “Garlic cloves contain a healthy dose of allicin, but you may still need a few cloves per day to feel the effects.” However, garlic supplementation can also be used to ward off viruses. A 2001 study published in the journal Advances In Therapy found a daily garlic supplement can reduce the number of colds by 63 percent compared to not taking supplements. Moreover, the average length of cold symptoms was also reduced to 70 percent, from five days in the control group to 1.5 days in garlic supplement group. These findings suggest the allicin-containing supplement has a protective effect against the common cold. 4. LOWERS BLOOD PRESSURE A garlic supplement a day may help keep your blood pressure at bay. Its active compounds can significantly reduce blood pressure comparable to the effects of prescribed drugs. Aged garlic extract between 600 to 1,500 milligrams (mg) was found to be just as effective as the drug Atenolol prescribed for hypertension in a 24-week period, according to a 2013 study published in the Pakistan Journal of Pharmaceutical Sciences. Garlic is believed to activate the production of the endothelium-derived relaxation factor, according to Ficek, due to the herb’s high amount of polysulfides — sulfur — containing molecules. This leads to smooth muscle relaxation and vasodilation (widening of blood vessels), following the relaxation of the smooth muscle in the vessel wall. Garlic supplements can achieve these effects efficiently without the bad breath compared to raw garlic. copy right : http://www.medicaldaily.com/
Views: 25 My Health